Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Roivant Pharmaceuticals
New York City, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Roivant has multiple late-stage assets with positive Phase 3 data in dermatomyositis for brepocitinib; NDA filing expected early 2026 with launch early 2027. Pipeline includes 4+ NDA/BLA filings and 8+ pivotal readouts planned over next three years.
- Therapeutic areas
- ImmunologyEndocrinologyNeurologyDermatologyRheumatologyPulmonologyOphthalmology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Partnerships
Pfizer (Priovant, TL1A programs)Sumitomo Dainippon Pharma (Sumitovant Biopharma)Roche (Telavant acquisition)Organon (Dermavant acquisition)
Beyond the preview
Go deeper on Roivant Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roivant Pharmaceuticals.